Role of JAK-STAT signaling in the pathogenic behavior of fibroblast-like synoviocytes in rheumatoid arthritis: Effect of the novel JAK inhibitor peficitinib
Open Access
- 1 September 2020
- journal article
- research article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 882, 173238
Abstract
No abstract availableKeywords
Funding Information
- Astellas Pharma
- Mitsubishi Tanabe Pharma Corporation
This publication has 35 references indexed in Scilit:
- Targeting Activated Synovial Fibroblasts in Rheumatoid Arthritis by PeficitinibFrontiers in Immunology, 2019
- Synovial Fluid and Serum Concentrations of Inflammatory Markers in Rheumatoid Arthritis, Psoriatic Arthritis and Osteoarthitis: A Systematic ReviewCurrent Rheumatology Reviews, 2017
- Constitutive Activation of Integrin α9 Augments Self-Directed Hyperplastic and Proinflammatory Properties of Fibroblast-like Synoviocytes of Rheumatoid ArthritisThe Journal of Immunology, 2017
- JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future ProspectsDrugs, 2017
- Hypoxia and STAT3 signalling interactions regulate pro-inflammatory pathways in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2015
- Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressorsNature Reviews Rheumatology, 2012
- Fibroblast‐like synoviocytes: key effector cells in rheumatoid arthritisImmunological Reviews, 2009
- Cyclosporine inhibition of vascular endothelial growth factor production in rheumatoid synovial fibroblastsArthritis & Rheumatism, 2002
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988
- Development of criteria for the classification and reporting of osteoarthritis: Classification of osteoarthritis of the kneeArthritis & Rheumatism, 1986